Market Report Focused on Vasopressin V1b Receptor - Pipeline Review, H2 2016

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted pipeline therapeutics.

The report provides comprehensive information on the Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) 
- The report reviews Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics

Reasons to buy

- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

AbbVie Inc. Allergan Plc Azevan Pharmaceuticals, Inc. Laboratorio ELEA S.A.C.I.F. y A. Orphan Therapeutics, LLC

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###